Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 12, 2006, Pages 1247-1253

  Santos, Stephanie A ^a   Uriel, Alison J ^a   Park, James S ^a   Lucas, Jennifer ^a   Carriero, Damaris ^a   Jaffe, David ^a   Dieterich, Douglas T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adefovir; Emtricitabine; Hepatitis B e antibody; Hepatitis B e antigen; Hepatitis B viral DNA; Hepatitis B virus; Lamivudine; Lamivudine resistance; Tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE; ASPARTATE AMINOTRANSFERASE; EMTRICITABINE; FAMCICLOVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADENINE; ADULT; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33750937268     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.meg.0000243877.17444.5e     Document Type: Article

References (33)

1. McQuillan GM, Townsend TR, Fields HA, Carroll M, Leahy M, Polk BF. Seroepidemiology of hepatitis B virus infection in the United States. Am J Med 1989; 87 (Suppl 3A):5S-10S.
2. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942-1956.
3. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LW, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347:168-174.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update and recommendations. Hepatology 2004; 39:857-861.
5. Keefe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2:87-106.
6. Allen ML, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrell DL, et al. Lamivudine clinical investigation group. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27:1670-1677.
7. Liaw YF, Cheung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119:172-180.
8. Lai CL, Dienstag J, Schiff E, Leung NWY, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants among lamivudine therapy of patients with chronic hepatitis B. Clin Infect Dis 2003; 36:687-696.
9. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816.
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800-807.
11. Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91-101.
12. Perrillo R, Hann H, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126:81-90.
13. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV DNA polymerase. Gastroenterology 2003; 125:292-297.
14. Yang H, Westland C, Delaney W 4th, Angus PW, Locarnini SA, Kitis G, et al. Complete genotypic and phenotypic analyses of HBV mutations identified in HBeAg-negative chronic hepatitis B patients receiving 96 weeks of adefovir dipivoxil (ADV) [Abstract]. Hepatology 2003; 38:705A.
15. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMALI, DAPD, penciclovir and lobucavir. J Viral Hepatitis 2000; 7:161-165.
16. Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002; 46:1734-1740.
17. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9:353-363.
18. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348:177-178.
19. Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-a and lamivudine therapy have failed. J Infect Dis 2002; 186:1844-1847.
20. Schildgen O, Schewe CK, Vogel M, Daumer M, Kaiser R, Weitner L, et al. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine therapy. AIDS 2004; 18:2325-2327.
21. van Bommel F, Schernick A, Hopf U, Berg T. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 2003; 124:586-587.
22. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2:266-272.
23. Mommeja-Marin H, Mondou E, Blum RH, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37:1309-1319.
24. Chen CJ, Yang HI, Su J, Jen CL, Kuo E, You SL, et al. Persistent elevation of serum HBV DNA is a risk factor for hepatocellular carcinoma: a long-term natural history study [Abstract]. Gastroenterology 2005; 128:A738.
25. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686.
26. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term (96 weeks) adefovir dipivoxil in HBeAg-negative chronic hepatitis results in significant virological, biochemical and histological improvement [Abstract]. Hepatology 2003; 38:273A.
27. Hadziyannis SJ, Tassopoulos NC, Chang TT, Heathcote EJ, Kitis G, Papnikolaou G, et al. Long-term adefovir treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B. Results after 5 years of therapy [Abstract]. Hepatology 2005; 42:754A.
28. van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40:1421-1425.
29. Saumoy M, Vidal F, Peraire J, Saukleda S, Martinez Vea A, Vilades C, et al. Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS 2004; 18:1741-1742.
30. Gish RG, Trinh H, Leung N, Chan FKL, Fried MW, Wright TL, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 2005; 43:60-66.
31. Shiffman ML, Ng TM, Krastev Z, Kotzev IA, Mechkov G, Kung NNS, et al. A double-blind placebo-controlled trial of emtricitabine (FTC, Emtriva) administered once daily for treatment of chronic hepatitis B virus (HBV) infection [Abstract]. Hepatology 2004; 40:172A.
32. Lau G, Cooksley H, Ribeiro RM, Powers KA, Bowden S, Mondou E, et al. Randomized, double-blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg ( +) chronic hepatitis B: efficacy and mechanisms of treatment response [Abstract]. Hepatology 2004; 40:272A.
33. Dienstag JL, Goldin RD, Heathcote EJ, Hann HWL, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105-117.